Side-by-side · Research reference

Kisspeptin-10vsTB-500

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/41 cited

BPhase 2HUMAN-REVIEWED8/46 cited

Kisspeptin-10

Neuropeptide · GPR54 Agonist

GnRH pulse generatorPrimary roleSilva 2026

Phase 1/2Clinical stage

GPR54/Kiss1RTarget receptorRønnekleiv 2026

IV / SQ · Investigational

TB-500

Thymosin β4 fragment · Healing

2 mgPer doseGoldstein 2012

Phase 2Evidence levelGoldstein 2012

~2 hrHalf-life

SQ or IM · Multiple sites · 2–3×/week

01Mechanism of Action

Parameter

Kisspeptin-10

TB-500

Primary target

GPR54/Kiss1R on hypothalamic GnRH neuronsRønnekleiv 2026 Collado-Sole 2026

G-actin (sequestering) + cell-surface integrinsGoldstein 2012

Pathway

Kisspeptin → GPR54 activation → GnRH neuronal depolarization → Pulsatile GnRH release → Pituitary LH/FSH secretionLages 2026 Rønnekleiv 2026

Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012 Malinda 1999

Downstream effect

Pulsatile LH surge, FSH elevation, gonadal steroidogenesis, gametogenesis initiationLages 2026

Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012

Feedback intact?

Yes — integrates estradiol, leptin, and IGF-1 signals to modulate HPG axisSilva 2026 Rønnekleiv 2026

Endogenous protein at baseline; supplementation amplifies

Origin

C-terminal decapeptide of KISS1 gene product; retains full biological activity of longer kisspeptin isoforms

17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012

Antibody development

—

02Dosage Protocols

Parameter

Kisspeptin-10

TB-500

Clinical trial dose

Phase 1/2 investigational

Dosing protocols vary by indication (hypothalamic amenorrhea, IVF trigger).

—

Route

IV or SQ administration

IV preferred in controlled trials for precise pulsatile delivery.

—

Evidence basis

Phase 1/2 trials

Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012

Half-life

Short (minutes)

Rapid clearance; pulsatile dosing mimics physiological GnRH pulse frequency.

~2 hours (estimated; tissue uptake longer)

Standard dose

—

2 mg per injectionGoldstein 2012

Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.

Frequency

—

2× per week (loading); then 1× per week (maintenance)

Lower / starter dose

—

1 mg per injection

Duration

—

4–8 weeks loading; longer maintenance for chronic injury

Reconstitution

—

Bacteriostatic water, 1–2 mL per 5 mg vial

Timing

—

Evening or pre-rest preferred (anecdotal)

04Side Effects & Safety

Parameter

Kisspeptin-10

TB-500

Ovarian hyperstimulation

Theoretical risk with supraphysiological dosing in fertility protocols

—

Headache

Mild, reported in early-phase trials

—

Nausea

Transient GI symptoms with IV bolus

—

Hot flashes

Vasomotor symptoms from LH surge

—

Injection site reaction

Erythema, mild discomfort (SQ route)

Mild erythema, transient pain

GI symptoms

—

Rare nausea (anecdotal)

Cancer risk

—

Theoretical via angiogenesis pathway

Lethargy / fatigue

—

Reported anecdotally during loading phase

Antibody formation

—

No data (no long-term human trials)

Pregnancy / OB

—

Avoid

Long-term safety

—

Unknown beyond Phase 2

Absolute Contraindications

Kisspeptin-10

·Active pregnancy
·Hormone-sensitive malignancy (breast, ovarian, endometrial)

TB-500

·Active malignancy (theoretical angiogenesis concern)
·Pregnancy / breastfeeding

Relative Contraindications

Kisspeptin-10

·Polycystic ovary syndrome (PCOS) without monitoring
·Uncontrolled thyroid dysfunction

TB-500

·Cancer history
·Concurrent VEGF inhibitor therapy

05Administration Protocol

Parameter

Kisspeptin-10

TB-500

1. Reconstitution (if lyophilized)

Reconstitute with sterile water or saline per protocol. Gently swirl — do not shake. Solution should be clear and colorless.

Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.

2. Route selection

IV infusion for pulsatile delivery in clinical trials; SQ for outpatient protocols. IV allows precise temporal control of GnRH pulse frequency.

SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.

3. Timing

Pulsatile dosing (e.g., every 60–90 min) mimics physiological GnRH pulse generator. Single-bolus protocols used for LH surge induction in fertility research.

Evening or pre-sleep is most common anecdotal timing.

4. Monitoring

Serial LH, FSH, estradiol measurements to confirm HPG axis activation. Ultrasound monitoring for ovarian response in fertility applications.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

5. Storage

Lyophilized: store at 2–8 °C, light-protected. Reconstituted: refrigerate, use within 24–48 hours per protocol.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Kisspeptin-10

— no documented stacks

TB-500

+ BPC-157

Strong

View BPC-157 →

TB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.

TB-500: 2 mg SQ · 2× per week
BPC-157: 250–500 mcg SQ · daily
Primary benefit: Combined angiogenesis + cell migration for tendon/ligament/muscle repair